...Nancy Stagliano, a biotech veteran who led True North...
...and Origenis. He is Neuron23’s CBO.Prior to True North...

...placebo (11.5% vs. 4.2%, p=0.0103). In the True North...

...in the same class as Arena’s etrasimod, met the primary endpoint in the Phase III True North...

...develop Zeposia to treat ulcerative colitis. Data are due in mid-year from the Phase III TRUE NORTH...

...Bioverativ Inc. in 2018, which in turn got the product through its own takeout of True North...
...Inc. in 2017 for $400 million up front and up to $425 million in milestones. True North’s...
...the classical pathway whereas C5 lies at the end of all three activation pathways (see “True North...

...candidates to treat rare blood diseases. Bioverativ obtained BIVV009 through its acquisition last year of True North...
...NASDAQ:BIVV), Waltham, Mass. Business: Hematology Jennie Walters ALN-AT3 Alprolix BIVV009 efmoroctocog alfa eftrenonacog alfa Eloctate fitusiran SAR439774 Alnylam Pharmaceuticals Inc. Bicycle Therapeutics Ltd. Bioverativ Inc. Sanofi Swedish Orphan Biovitrum AB True North...

...candidates to treat rare blood diseases. Bioverativ obtained BIVV009 through its acquisition last year of True North...
...Bioverativ expect their deal to close within three months. Jennie Walters ALN-AT3 Alprolix BIVV009 Eloctate fitusiran SAR439774 TNT009 Alnylam Pharmaceuticals Inc. Bicycle Therapeutics Ltd. Biogen Inc. Bioverativ Inc. Sanofi True North...

...ECTRIMS-ACTRIMS meeting in Paris. In 2H18, Celgene plans to complete enrollment of the Phase III TRUE NORTH...

...ECTRIMS-ACTRIMS meeting in Paris. In 2H18, Celgene plans to complete enrollment of the Phase III TRUE NORTH...

...modulator Gilenya fingolimod, without sacrificing efficacy. The compound is also in the ongoing Phase III TRUE NORTH...